AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR 8,765.10
+36.60 (0.42%)
At close: Aug 8, 2025
Allakos Revenue
In the fiscal year ending March 31, 2025, AstraZeneca Pharma India had annual revenue of 17.16B INR with 32.48% growth. AstraZeneca Pharma India had revenue of 4.80B in the quarter ending March 31, 2025, with 25.39% growth.
Revenue
17.16B
Revenue Growth
+32.48%
P/S Ratio
12.77
Revenue / Employee
21.40M
Employees
802
Market Cap
219.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | 8.14B | -182.50M | -2.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 639.28B |
AstraZeneca Pharma India News
- 27 days ago - AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication - Business Upturn
- 2 months ago - AstraZeneca Pharma India shares rally over 7% after strong Q4 results - Business Upturn
- 2 months ago - AstraZeneca Pharma receives CDSCO nod for expanded use of Fasenra in India - Business Upturn
- 5 months ago - AstraZeneca Pharma gets approval for additional indication of Durvalumab (Imfinzi) in India - Business Upturn
- 5 months ago - AstraZeneca receives approval to import Lokelma for hyperkalaemia treatment in India - Business Upturn
- 7 months ago - AstraZeneca receives approval to import and distribute Eculizumab - Business Upturn
- 9 months ago - AstraZeneca Pharma India gets sale approval for additional indication of Olaparib film-coated tablets - Business Upturn
- 9 months ago - Astrazeneca Pharma India shares surge 3% on Breztri Aerosphere launch announcement - Business Upturn